New Jersey has elected six new companies to potentially operate in its medical cannabis market, including 3 publicly traded ventures.

On Monday (December 17), the New Jersey Department of Health (DOH) confirmed six new selections for companies to apply for permits in order to open medical marijuana shops.


Among the winners were public US multi-state operators Green Thumb Industries (CSE:GTII), MPX Bioceutical (CSE:MPX) and TerrAscend (CSE:TER).

Health Commissioner Dr. Shereef Elnahal said the DOH will meet with the six applicants “early next year” to hash out the specifics of growing product and when stores would be opening in the given region.

Officials assigned each company to a specific region in the state. The DOH confirmed some applicants requested more than one region but the agency is assigning only one region per applicant.


Matthew Johnson, TerrAscend’s president, said in a statement to shareholders thanks to the approval the company will be able to move forward with the build out of secured locations in the state.

TerrAscend earned an entrance to the state’s marijuana market thanks to its majority owned subsidiary NETA NJ, which earned a license for the northern town of Phillipsburg.

“Expansion in New Jersey is firmly in line with the company’s strategic goals of increasing its footprint in limited license markets and distributing brands at scale,” GTI founder and CEO Ben Kovler said.

GTI earned its license for the Patterson community in the state.

After confirmation of its licenses Beth Stavola, chief operating officer and president of US operations for MPX, told The Press of Atlantic City the company’s application obtained the highest score from all 146 submitted applicants.

Stavola joined the board of trustees for the New Jersey Cannabis Industry Association at the start of 2018 and will be moving to iAnthus Capital Holdings (CSE:IAN) as part of a merger between the two companies.

Fellow US multi-state operator iAnthus will acquire the existing US assets from MPX in a confirmed deal.

According to the DOH, New Jersey counts for approximately 38,000 active medical cannabis patients.

The state is also looking to add recreational products to its market as lawmakers moved forward with a legalization adjustment to the law in November, which could open the market as early as January.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less